Incisive Surgical, Innocutis sign marketing agreement for INSORB Absorbable Skin Stapler

Innocutis Medical, a dermatology company focused on novel surgical devices and specialty pharmaceuticals, is pleased to announce an exclusive marketing agreement with Incisive Surgical, Inc. (Plymouth MN) for the sales and marketing rights within the dermatology market for the patented INSORB® Absorbable Skin Stapler, a revolutionary new modality for skin closure. The INSORB Stapler uses bioabsorbable staples that are placed under the skin and dissolve in the body within a matter of months. The staples, which are comprised of the same material as the leading bioabsorbable sutures, break down naturally, meaning there is no need for post-operative removal. With over a half a million surgical cases performed within the hospital market, INSORB has developed a solid and proven track record. INSORB's introduction to the dermatology community will allow for increased surgical efficiency, improved cosmetic outcomes, and reduced risk of infection over traditional suture techniques. Innocutis will introduce INSORB to the dermatology community February 5th, 2011 at the American Academy of Dermatology in New Orleans, LA.

"We are pleased to join forces with INNOCUTIS to bring our technology to this exciting new market for us," said John L. Shannon, Jr., President and Chief Executive Officer of Incisive Surgical. "We have enjoyed much success in the surgical arena, including obstetrics & gynecology, orthopedic, general and plastic surgery, and look forward to offering the profound benefits of this technology to the dermatology community."

"We believe that our focus on both medical and surgical dermatology sets us apart as a company that understands the growing needs of the dermatology specialty," said Chuck Jenkins, Vice President of Sales and Marketing for Innocutis. "We are committed to being 'best-in-class' in skin-related therapies and providing clinicians with improved solutions for managing their daily challenges."

Innocutis believes the INSORB absorbable subcuticular stapler will greatly enhance the efficiency in dermatologists' offices nationally while providing a marked advancement in the cosmetic outcome seen by their patients. The INSORB Device contains 30 sterile staples comprised of 70% PLA and 30% PGA producing a benign polymer that is not only strong but also dissolves in 90-120 days. For dermatologists, they now have the ability to utilize a subcuticular closure modality without the need for post operative suture removal. INNOCUTIS intends to have their representatives participate in surgical scenarios with their doctors to ensure surgical technique is followed and outcomes are exceptional.